Reporting suspected adverse reactions is essential to the continuous post-marketing assessment of the benefit-risk balance of pharmaceutical products. We remind healthcare professionals to fulfill their reporting obligations in accordance with the Administrative Measures for the Reporting and Monitoring of Adverse Drug Reactions (Decree No. 81 of the Ministry of Health). Additionally, THEDERMA provides the following reporting channels. You are welcome to inform us promptly of any suspected adverse reactions to THEDERMA pharmaceutical products:

Email: pv@thederma.com